Sign inJoin waitlistJoin the waitlist

Hun Lee

Internal Medicine Residency · University of Texas M D Anderson Cancer Center

Credentials: · · ·

History

University of Texas M D Anderson Cancer Center
2025–Present
Jacobs School of Medicine and Biomedical Sciences at the University at Buffalo
2002–2006

Research

Double hit lymphoma: the MD Anderson Cancer Center clinical experience
British Journal of Haematology · 2014 · 309 citations
Pembrolizumab in relapsed or refractory Hodgkin lymphoma: 2-year follow-up of KEYNOTE-087
Blood · 2019 · 274 citations
Nivolumab for Newly Diagnosed Advanced-Stage Classic Hodgkin Lymphoma: Safety and Efficacy in the Phase II CheckMate 205 Study
Journal of Clinical Oncology · 2019 · 200 citations

Jason Westin
48 papers
Loretta Nastoupil
47 papers · 3 as a fellow
Luis Fayad
46 papers
Sattva Neelapu
44 papers
Christopher Flowers
31 papers
Maria Rodriguez
30 papers
NF
Nathan Fowler
30 papers
Paolo Strati
30 papers
Fredrick Hagemeister
29 papers
Sairah Ahmed
29 papers
Chelsea Pinnix
28 papers
Ranjit Nair
28 papers

Clinical trials

PET Adapted Brentuximab Vedotin and Pembrolizumab in Combination With Doxorubicin and Dacarbazine in Classic Hodgkin Lymphoma
Principal investigator · Active not recruiting · Phase 2
M.D. Anderson Cancer Center
2023–2027
Ixazomib and Rituximab in Treating Patients With Relapsed or Refractory Mantle Cell Lymphoma
Principal investigator · Terminated · Phase 2
M.D. Anderson Cancer Center
2019–2025
Trial of PCI-32765 (BTK Inhibitor) in Combination With Carfilzomib in Relapse/Refractory Mantle Cell Lymphoma
Principal investigator · Terminated · Phase 1
M.D. Anderson Cancer Center
2015–2018
A Phase II Study of Carfilzomib in the Treatment of Relapsed/Refractory Mantle Cell Lymphoma
Principal investigator · Terminated · Phase 2
M.D. Anderson Cancer Center
2014–2017